Iovance Biotherapeutics Surges After Lifting 2026 Revenue Outlook

By: Quiver PriceTracker

Posted: 2 hours ago / Sept. 29, 2026 5:38 p.m. UTC

IOVA

Iovance Biotherapeutics (IOVA) is up 38.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be driven primarily by Iovance’s decision on September 29, 2026 to raise its full-year revenue guidance, signaling stronger-than-expected commercial demand for Amtagvi and Proleukin. Investors also seem to be reacting to improved visibility into second-half revenue and the view that manufacturing and treatment-center expansion are supporting faster uptake.

Details:

Iovance raised full-year 2026 total revenue guidance to $410 million to $420 million, up from its prior range of $350 million to $370 million.

The company said the higher outlook was driven by strong U.S. demand for Amtagvi and Proleukin, with the new midpoint about $55 million above the prior midpoint.

Management pointed to increasing patient demand and its current manufacturing schedule as giving stronger visibility into third- and fourth-quarter revenue.

Iovance also said it recently posted record second-quarter 2026 product revenue of $99.3 million and expanded its authorized treatment center network to about 100 sites, with a goal of at least 110 by year-end.

Sources:

SEC, GlobeNewswire, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IOVA Hedge Fund Activity

We have seen 167 institutional investors add shares of $IOVA stock to their portfolio, and 128 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

INVENOMIC CAPITAL MANAGEMENT LP removed 7,012,956 shares (-82.5%) from their portfolio in Q2 2026, for an estimated $29,173,896
BLACKROCK, INC. added 5,877,176 shares (+18.9%) to their portfolio in Q2 2026, for an estimated $24,449,052
TWO SIGMA INVESTMENTS, LP added 5,323,264 shares (+38.9%) to their portfolio in Q2 2026, for an estimated $22,144,778
JUPITER ASSET MANAGEMENT LTD added 4,535,080 shares (+inf%) to their portfolio in Q2 2026, for an estimated $18,865,932
DIMENSIONAL FUND ADVISORS LP added 3,814,747 shares (+144.2%) to their portfolio in Q2 2026, for an estimated $15,869,347
GOLDMAN SACHS GROUP INC removed 3,663,726 shares (-41.8%) from their portfolio in Q2 2026, for an estimated $15,241,100
BANK OF AMERICA CORP /DE/ removed 3,496,535 shares (-41.2%) from their portfolio in Q2 2026, for an estimated $14,545,585

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.